Aurinia Pharmaceuticals Inc. – NASDAQ:AUPH
Aurinia Pharmaceuticals stock price today
$12.15
+2.95
+32.07%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Aurinia Pharmaceuticals stock price monthly change
+63.99%
month
Aurinia Pharmaceuticals stock price quarterly change
+63.99%
quarter
Aurinia Pharmaceuticals stock price yearly change
-0.97%
year
Aurinia Pharmaceuticals key metrics
Market Cap | 1.28B |
Enterprise value | 1.46B |
P/E | -14.59 |
EV/Sales | 10.94 |
EV/EBITDA | -14.88 |
Price/Sales | 11.58 |
Price/Book | 3.82 |
PEG ratio | -0.36 |
EPS | -0.43 |
Revenue | 191.40M |
EBITDA | -39.33M |
Income | -62.56M |
Revenue Q/Q | 46.19% |
Revenue Y/Y | 30.37% |
Profit margin | -80.71% |
Oper. margin | -83.17% |
Gross margin | 95.77% |
EBIT margin | -83.17% |
EBITDA margin | -20.55% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAurinia Pharmaceuticals stock price history
Aurinia Pharmaceuticals stock forecast
Aurinia Pharmaceuticals financial statements
| Jun 2023 | 41.49M | -11.49M | -27.7% |
|---|---|---|---|
| Sep 2023 | 54.51M | -13.44M | -24.67% |
| Dec 2023 | 45.09M | -26.87M | -59.6% |
| Mar 2024 | 50.30M | -10.74M | -21.37% |
| 2025 | 282.30M | 71.19M | 25.22% |
|---|---|---|---|
| 2026 | 349.52M | 133.20M | 38.11% |
| 2027 | 393.19M | 168.30M | 42.8% |
| 2028 | 449.35M | 200.53M | 44.63% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 548900000 | 156.60M | 28.53% |
|---|---|---|---|
| Sep 2023 | 555013000 | 163.13M | 29.39% |
| Dec 2023 | 548062000 | 170.10M | 31.04% |
| Mar 2024 | 516634000 | 157.15M | 30.42% |
| Jun 2023 | -2.82M | -5.60M | 1.14M |
|---|---|---|---|
| Sep 2023 | -13.27M | -19.70M | -2.33M |
| Dec 2023 | 14.81M | -6.19M | -5.53M |
| Mar 2024 | -18.59M | 49.23M | -15.05M |
Aurinia Pharmaceuticals alternative data
Aurinia Pharmaceuticals
| 5 Mar 2023 | 11 |
|---|---|
| 12 Mar 2023 | 10 |
| 19 Mar 2023 | 3 |
| 26 Mar 2023 | 7 |
| 2 Apr 2023 | 4 |
| 9 Apr 2023 | 11 |
| 16 Apr 2023 | 9 |
| 23 Apr 2023 | 9 |
| 30 Apr 2023 | 6 |
| 7 May 2023 | 10 |
| 14 May 2023 | 6 |
| 21 May 2023 | 8 |
| 28 May 2023 | 6 |
| 4 Jun 2023 | 5 |
| 11 Jun 2023 | 8 |
| 18 Jun 2023 | 7 |
| 25 Jun 2023 | 8 |
| 2 Jul 2023 | 6 |
| 9 Jul 2023 | 7 |
| 16 Jul 2023 | 10 |
Autoimmune Disease
| 21 May 2023 | 41 |
|---|---|
| 28 May 2023 | 39 |
| 4 Jun 2023 | 39 |
| 11 Jun 2023 | 37 |
| 18 Jun 2023 | 42 |
| 25 Jun 2023 | 41 |
| 2 Jul 2023 | 43 |
| 9 Jul 2023 | 41 |
| 16 Jul 2023 | 41 |
| 23 Jul 2023 | 41 |
| 30 Jul 2023 | 42 |
| 6 Aug 2023 | 43 |
| 13 Aug 2023 | 45 |
| 20 Aug 2023 | 38 |
| 27 Aug 2023 | 43 |
| 3 Sep 2023 | 38 |
| 10 Sep 2023 | 39 |
| 17 Sep 2023 | 43 |
| 24 Sep 2023 | 46 |
| 1 Oct 2023 | 46 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Aug 2023 | 9 |
|---|---|
| Sep 2023 | 9 |
| Oct 2023 | 0 |
| Nov 2023 | 11 |
| Dec 2023 | 8 |
| Jan 2024 | 4 |
| Feb 2024 | 4 |
| Apr 2024 | 11 |
| May 2024 | 9 |
| Jun 2024 | 10 |
| Jul 2024 | 6 |
| Aug 2023 | 300 |
|---|---|
| Sep 2023 | 300 |
| Oct 2023 | 300 |
| Nov 2023 | 300 |
| Dec 2023 | 300 |
| Jan 2024 | 300 |
| Feb 2024 | 300 |
| Mar 2024 | 300 |
| Apr 2024 | 300 |
| May 2024 | 300 |
| Jun 2024 | 300 |
| Jul 2024 | 300 |
Aurinia Pharmaceuticals other data
33.09%
+3.00%
of AUPH is owned by hedge funds
175
-9
42.49M
+3.84M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 45943 |
| Mar 2024 | 0 | 277979 |
| May 2024 | 0 | 21958 |
| Aug 2024 | 0 | 18249 |
| Nov 2024 | 0 | 9798 |
| Dec 2024 | 1200000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | TANG KEVIN director | Common Shares | 500,000 | $9.09 | $4,545,000 | ||
Purchase | TANG KEVIN director | Common Shares | 400,000 | $9.01 | $3,604,000 | ||
Purchase | TANG KEVIN director | Common Shares | 300,000 | $8.91 | $2,673,000 | ||
Sale | BAILEY JEFFREY ALLEN director | Common Stock | 4,557 | $8.43 | $38,416 | ||
Sale | SMITH KAREN L. director | Common Stock | 5,241 | $8.43 | $44,182 | ||
Option | BAILEY JEFFREY ALLEN director | Common Stock | 17,913 | N/A | N/A | ||
Option | BAILEY JEFFREY ALLEN director | Restricted Stock Units | 17,913 | N/A | N/A | ||
Option | SMITH KAREN L. director | Common Stock | 17,913 | N/A | N/A | ||
Option | SMITH KAREN L. director | Restricted Stock Units | 17,913 | N/A | N/A | ||
Sale | HABIG SCOTT MICHAEL officer: Chief Commercial Officer | Common Stock | 18,249 | $5.31 | $96,902 |
| Patent |
|---|
Application Filling date: 4 Apr 2022 Issue date: 21 Jul 2022 |
Application Filling date: 12 Apr 2021 Issue date: 4 Nov 2021 |
Grant Utility: Ophthalmic compositions Filling date: 8 Feb 2019 Issue date: 13 Apr 2021 |
Grant Filling date: 30 Jun 2014 Issue date: 29 Sep 2020 |
Application Filling date: 8 Feb 2019 Issue date: 9 Jan 2020 |
Grant Filling date: 14 Aug 2017 Issue date: 12 Nov 2019 |
| Quarter | Transcript |
|---|---|
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 15 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Peter S. Greenleaf M.B.A. (1970) Pres, Chief Executive Officer & Director | $1,390,000 |
Mr. Massimiliano Colao (1965) Chief Commercial Officer | $719,790 |
Mr. Matthew Maxwell Donley M.B.A. (1969) Executive Vice President of Operations & Strategy | $627,510 |
Mr. Joseph M. Miller CPA (1974) Chief Financial Officer | $614,270 |
| Mr. Stephen P. Robertson (1982) Executive Vice President, Gen. Counsel, Corporation Sec. & Chief Compliance Officer | $193,430 |
Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth
3 Biotech Stocks With Notable Insider Buying
Aurinia Pharmaceuticals Appears Undervalued
3 Biotech Names Under $10 I Own
Showcasing Seeking Alpha's April 2024 New Analysts
Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
Aurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum Going
Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Aurinia Pharmaceuticals: Reassessing As It Gains Traction
-
What's the price of Aurinia Pharmaceuticals stock today?
One share of Aurinia Pharmaceuticals stock can currently be purchased for approximately $12.15.
-
When is Aurinia Pharmaceuticals's next earnings date?
Unfortunately, Aurinia Pharmaceuticals's (AUPH) next earnings date is currently unknown.
-
Does Aurinia Pharmaceuticals pay dividends?
No, Aurinia Pharmaceuticals does not pay dividends.
-
How much money does Aurinia Pharmaceuticals make?
Aurinia Pharmaceuticals has a market capitalization of 1.28B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 30.95% to 175.51M US dollars.
-
What is Aurinia Pharmaceuticals's stock symbol?
Aurinia Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "AUPH".
-
What is Aurinia Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Aurinia Pharmaceuticals?
Shares of Aurinia Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aurinia Pharmaceuticals's key executives?
Aurinia Pharmaceuticals's management team includes the following people:
- Mr. Peter S. Greenleaf M.B.A. Pres, Chief Executive Officer & Director(age: 55, pay: $1,390,000)
- Mr. Massimiliano Colao Chief Commercial Officer(age: 60, pay: $719,790)
- Mr. Matthew Maxwell Donley M.B.A. Executive Vice President of Operations & Strategy(age: 56, pay: $627,510)
- Mr. Joseph M. Miller CPA Chief Financial Officer(age: 51, pay: $614,270)
- Mr. Stephen P. Robertson Executive Vice President, Gen. Counsel, Corporation Sec. & Chief Compliance Officer(age: 43, pay: $193,430)
-
How many employees does Aurinia Pharmaceuticals have?
As Jul 2024, Aurinia Pharmaceuticals employs 300 workers.
-
When Aurinia Pharmaceuticals went public?
Aurinia Pharmaceuticals Inc. is publicly traded company for more then 11 years since IPO on 3 Sep 2014.
-
What is Aurinia Pharmaceuticals's official website?
The official website for Aurinia Pharmaceuticals is auriniapharma.com.
-
Where are Aurinia Pharmaceuticals's headquarters?
Aurinia Pharmaceuticals is headquartered at 4464 Markham Street, Victoria, BC.
-
How can i contact Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals's mailing address is 4464 Markham Street, Victoria, BC and company can be reached via phone at +1 250 708 4272.
Aurinia Pharmaceuticals company profile:
Aurinia Pharmaceuticals Inc.
auriniapharma.comExchange:
NASDAQ
Full time employees:
300
Industry:
Biotechnology
Sector:
Healthcare
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
4464 Markham Street
Victoria, BC V8Z 7X8
Victoria, BC V8Z 7X8
CIK: 0001600620
ISIN: CA05156V1022
CUSIP: 05156V102
